An in silico reverse vaccinology approach to design a novel multiepitope peptide vaccine for non-small cell lung cancers
Non-small cell lung cancer (NSCLC) is the most prevalent and fatal lung cancer. The multiepitope vaccine is one of the immunotherapies successfully applied to treat NSCLC. We designed a multiepitope vaccine with MHC-I, MHC-II, CTL, and linear B cell epitopes of MAGE-A3, EGF, and MUC-1 oncoproteins e...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Informatics in Medicine Unlocked |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352914823000114 |
| _version_ | 1811160830725586944 |
|---|---|
| author | Md Mijanur Rahman Md Habib Ullah Masum Asma Talukder Rekha Akter |
| author_facet | Md Mijanur Rahman Md Habib Ullah Masum Asma Talukder Rekha Akter |
| author_sort | Md Mijanur Rahman |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) is the most prevalent and fatal lung cancer. The multiepitope vaccine is one of the immunotherapies successfully applied to treat NSCLC. We designed a multiepitope vaccine with MHC-I, MHC-II, CTL, and linear B cell epitopes of MAGE-A3, EGF, and MUC-1 oncoproteins employing in silico immunoinformatics approach. The structural assessment of the vaccine showed it as a well-stable protein (Z score of −7.53). The molecular docking between the vaccine and human receptors (TLR-2, TLR-4, MHC-I and MHC-II alleles) implied a high affinity of the vaccine to the receptors. The codon optimization and in silico cloning of the vaccine into the pET-28a (+) plasmid of the E. coli K12 strain revealed its potentiality upon expression (CAI value of 0.9607). Furthermore, immune simulation of the vaccine depicted its ability to stimulate immune responses (B cell, T cell, antibody, and cytokines) against NSCLC. Almost all developed NSCLC vaccines cannot treat or prevent NSCLC satisfactorily, and there is still no multiepitope vaccine available that contains all three significant oncoproteins; therefore, our designed vaccine could be a significant weapon against NSCLC. This novel multiepitope vaccine could be developed upon considering its safety, efficacy, and adverse effects on humans through further studies. |
| first_indexed | 2024-04-10T06:04:59Z |
| format | Article |
| id | doaj.art-bc180c7c5af9457b88829b737adacdf4 |
| institution | Directory Open Access Journal |
| issn | 2352-9148 |
| language | English |
| last_indexed | 2024-04-10T06:04:59Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Informatics in Medicine Unlocked |
| spelling | doaj.art-bc180c7c5af9457b88829b737adacdf42023-03-03T04:24:51ZengElsevierInformatics in Medicine Unlocked2352-91482023-01-0137101169An in silico reverse vaccinology approach to design a novel multiepitope peptide vaccine for non-small cell lung cancersMd Mijanur Rahman0Md Habib Ullah Masum1Asma Talukder2Rekha Akter3Department of Microbiology, Noakhali Science and Technology University, Noakhali, 3814, Bangladesh; Microbiology, Cancer and Bioinformatics Research Group, Noakhali Science and Technology University, Noakhali, 3814, Bangladesh; Menzies Health Institute Queensland, School of Pharmacy and Medical Sciences, Griffith University, Gold Coast Campus, Parklands Drive, Southport, QLD, 4215, Australia; Corresponding author. Department of Microbiology, Noakhali Science and Technology University, Noakhali, 3814, BangladeshDepartment of Microbiology, Noakhali Science and Technology University, Noakhali, 3814, Bangladesh; Microbiology, Cancer and Bioinformatics Research Group, Noakhali Science and Technology University, Noakhali, 3814, BangladeshMicrobiology, Cancer and Bioinformatics Research Group, Noakhali Science and Technology University, Noakhali, 3814, Bangladesh; Department of Biotechnology and Genetic Engineering, Noakhali Science and Technology University, Noakhali-3814, BangladeshDepartment of Biochemistry and Molecular Biology, University of Chittagong, Chattogram, 4331, BangladeshNon-small cell lung cancer (NSCLC) is the most prevalent and fatal lung cancer. The multiepitope vaccine is one of the immunotherapies successfully applied to treat NSCLC. We designed a multiepitope vaccine with MHC-I, MHC-II, CTL, and linear B cell epitopes of MAGE-A3, EGF, and MUC-1 oncoproteins employing in silico immunoinformatics approach. The structural assessment of the vaccine showed it as a well-stable protein (Z score of −7.53). The molecular docking between the vaccine and human receptors (TLR-2, TLR-4, MHC-I and MHC-II alleles) implied a high affinity of the vaccine to the receptors. The codon optimization and in silico cloning of the vaccine into the pET-28a (+) plasmid of the E. coli K12 strain revealed its potentiality upon expression (CAI value of 0.9607). Furthermore, immune simulation of the vaccine depicted its ability to stimulate immune responses (B cell, T cell, antibody, and cytokines) against NSCLC. Almost all developed NSCLC vaccines cannot treat or prevent NSCLC satisfactorily, and there is still no multiepitope vaccine available that contains all three significant oncoproteins; therefore, our designed vaccine could be a significant weapon against NSCLC. This novel multiepitope vaccine could be developed upon considering its safety, efficacy, and adverse effects on humans through further studies.http://www.sciencedirect.com/science/article/pii/S2352914823000114Non-small cell lung cancerReverse vaccinologyMultiepitope vaccineMAGE-A3EGFMUC-1 |
| spellingShingle | Md Mijanur Rahman Md Habib Ullah Masum Asma Talukder Rekha Akter An in silico reverse vaccinology approach to design a novel multiepitope peptide vaccine for non-small cell lung cancers Informatics in Medicine Unlocked Non-small cell lung cancer Reverse vaccinology Multiepitope vaccine MAGE-A3 EGF MUC-1 |
| title | An in silico reverse vaccinology approach to design a novel multiepitope peptide vaccine for non-small cell lung cancers |
| title_full | An in silico reverse vaccinology approach to design a novel multiepitope peptide vaccine for non-small cell lung cancers |
| title_fullStr | An in silico reverse vaccinology approach to design a novel multiepitope peptide vaccine for non-small cell lung cancers |
| title_full_unstemmed | An in silico reverse vaccinology approach to design a novel multiepitope peptide vaccine for non-small cell lung cancers |
| title_short | An in silico reverse vaccinology approach to design a novel multiepitope peptide vaccine for non-small cell lung cancers |
| title_sort | in silico reverse vaccinology approach to design a novel multiepitope peptide vaccine for non small cell lung cancers |
| topic | Non-small cell lung cancer Reverse vaccinology Multiepitope vaccine MAGE-A3 EGF MUC-1 |
| url | http://www.sciencedirect.com/science/article/pii/S2352914823000114 |
| work_keys_str_mv | AT mdmijanurrahman aninsilicoreversevaccinologyapproachtodesignanovelmultiepitopepeptidevaccinefornonsmallcelllungcancers AT mdhabibullahmasum aninsilicoreversevaccinologyapproachtodesignanovelmultiepitopepeptidevaccinefornonsmallcelllungcancers AT asmatalukder aninsilicoreversevaccinologyapproachtodesignanovelmultiepitopepeptidevaccinefornonsmallcelllungcancers AT rekhaakter aninsilicoreversevaccinologyapproachtodesignanovelmultiepitopepeptidevaccinefornonsmallcelllungcancers AT mdmijanurrahman insilicoreversevaccinologyapproachtodesignanovelmultiepitopepeptidevaccinefornonsmallcelllungcancers AT mdhabibullahmasum insilicoreversevaccinologyapproachtodesignanovelmultiepitopepeptidevaccinefornonsmallcelllungcancers AT asmatalukder insilicoreversevaccinologyapproachtodesignanovelmultiepitopepeptidevaccinefornonsmallcelllungcancers AT rekhaakter insilicoreversevaccinologyapproachtodesignanovelmultiepitopepeptidevaccinefornonsmallcelllungcancers |